Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz 400 mg versus 600 mg cerebrospinal fluid exposure substudy in HIV
ACTRN12612001194853Phase 3Completed
- Sponsor
- The Kirby Institute
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Efavirenz 600 mg + tenofovir/emtricitabine with Efavirenz 400 mg + tenofovir/emtricitabine + placebo (2 arms). Primary endpoint: CSF efavirenz exposure at 400 mg and 600 mg daily. Started Sep 2011; status: completed.
02
Drugs
efavirenztenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12612001194853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001194853.